|
MED13L expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.6242562850266E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.11022302462516E-16 |
| Normal-vs-Stage2 |
6.75480005263296E-10 |
| Normal-vs-Stage3 |
2.22044604925031E-16 |
| Normal-vs-Stage4 |
<1E-12 |
| Stage1-vs-Stage2 |
3.507600E-01 |
| Stage1-vs-Stage3 |
8.580000E-02 |
| Stage1-vs-Stage4 |
2.376000E-03 |
| Stage2-vs-Stage3 |
3.258300E-02 |
| Stage2-vs-Stage4 |
3.522700E-03 |
| Stage3-vs-Stage4 |
2.147000E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
<1E-12 |
| Normal-vs-AfricanAmerican |
3.12940007241025E-10 |
| Normal-vs-Asian |
1.62547753035369E-12 |
| Caucasian-vs-AfricanAmerican |
6.079000E-01 |
| Caucasian-vs-Asian |
3.872000E-01 |
| AfricanAmerican-vs-Asian |
2.845200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.62503344114384E-12 |
| Normal-vs-Female |
1.62447832963153E-12 |
| Male-vs-Female |
2.740600E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
6.21724893790088E-15 |
| Normal-vs-Age(41-60Yrs) |
4.44089209850063E-16 |
| Normal-vs-Age(61-80Yrs) |
1.88737914186277E-15 |
| Normal-vs-Age(81-100Yrs) |
4.20600000000659E-05 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
8.763400E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
5.499200E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
6.631200E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
6.973000E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
7.877800E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
8.190200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
7.625000E-04 |
| Classical-VS-Follicular |
1.118630E-01 |
| Classical-VS-Other |
5.253000E-01 |
| Classical-VS-Normal |
2.48689957516035E-14 |
| Tall-VS-Follicular |
4.595600E-04 |
| Tall-VS-Other |
3.952200E-01 |
| Tall-VS-Normal |
1.62447832963153E-12 |
| Follicular-VS-Other |
3.942800E-01 |
| Follicular-VS-Normal |
2.81819999559119E-08 |
| Other-VS-Normal |
9.96149999999973E-05 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
<1E-12 |
| Normal-vs-N1 |
1.62458935193399E-12 |
| N0-vs-N1 |
4.685500E-02 |
|
|
